Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression

Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF), a Toronto-based psychedelics company, is launching a randomized clinical trial using psilocybin for adults with treatment-resistant depression.

A number of organizations and for-profit companies in the psychedelics space are looking at the clinical applications of psilocybin in the treatment of depression, including the Usona Institute and Compass Pathways (NASDAQ: CMPS).

However, …

Full story available on Benzinga.com

More Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression